Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Marek

Showing results (111-120 of 144) with videos related to

Pageof 15
Sort By:
Journal of Parkinson'S Disease|December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialM Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
Journal of Parkinson'S Disease|July 16, 2019
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's DiseaseDiane Stephenson, Derek Hill, Jesse M Cedarbaum, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2024
Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmiaDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
Annals of Neurology|May 14, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers InitiativeEthan G Brown, Lana M Chahine, Roseanne D Dobkin, et al.
Annals of Neurology|December 25, 2024
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein DiseaseEthan G Brown, Lana M Chahine, Andrew Siderowf, et al.
Annals of Clinical and Translational Neurology|December 15, 2020
Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorderLana M Chahine, Michael C Brumm, Chelsea Caspell-Garcia, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 12, 2015
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficitsNorbert Schuff, I-Wei Wu, Shannon Buckley, et al.
Annals of Clinical and Translational Neurology|April 22, 2026
Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined SynucleinopathyDaniel Weintraub, Michele K York, Roseanne Dobkin, et al.
Pageof 15

Showing results (111-120 of 144) with videos related to

Sort By:
Pageof 15
Journal of Parkinson'S Disease|December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialM Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
Journal of Parkinson'S Disease|July 16, 2019
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's DiseaseDiane Stephenson, Derek Hill, Jesse M Cedarbaum, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2024
Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmiaDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
Annals of Neurology|May 14, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers InitiativeEthan G Brown, Lana M Chahine, Roseanne D Dobkin, et al.
Annals of Neurology|December 25, 2024
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein DiseaseEthan G Brown, Lana M Chahine, Andrew Siderowf, et al.
Annals of Clinical and Translational Neurology|December 15, 2020
Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorderLana M Chahine, Michael C Brumm, Chelsea Caspell-Garcia, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 12, 2015
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficitsNorbert Schuff, I-Wei Wu, Shannon Buckley, et al.
Annals of Clinical and Translational Neurology|April 22, 2026
Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined SynucleinopathyDaniel Weintraub, Michele K York, Roseanne Dobkin, et al.
Pageof 15